Showing 1196 results
- Media Release /Everolimus is the first adjunctive therapy shown in a prospective randomized Phase III study to achieve clinically significant seizure control in TSC patients[1] Seizures are the most…
- Media Release /Sandoz' epoetin alfa product offering has already generated more than 400,000[1] patient years of experience worldwide EC approval expands Sandoz biosimilar offering to the healthcare community…
- Media Release /EU approval of Revolade expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have not responded to other therapies Two formulations approved: once-daily…
- Media Release /New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless of prior heart…
- Media Release /Updated segment financials reflect transfer of Ophthalmic Pharmaceuticals franchise from Alcon to Pharmaceuticals, and 19 mature products from Pharmaceuticals to Sandoz, as outlined in Q4 and FY…
- Media Release /Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical dataBreast and gastric cancers are among most common types of cancer, accounting together for nearly half…
- Media Release /New data at AAD 2016 shows Cosentyx® is significantly more efficacious than Stelara in sustaining skin clearance (PASI 90 to PASI 100) at 52 weeks[1] Cosentyx delivered and sustained skin…
- Media Release /In advanced progressive, nonfunctional NET, Afinitor is the first approved treatment for patients with lung NET and the first oral therapy for GI NET Approval helps fulfill unmet need as…
- Media Release /Shareholders approve 19th consecutive dividend increase to CHF 2.70 (+4%) per share for 2015 Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis Board of Directors as well as…
- Media Release /Les actionnaires approuvent la 19e hausse consécutive du dividende, à CHF 2,70 par action (+4%) au titre de l'exercice 2015. Le Dr Joerg Reinhardt est confirmé par les actionnaires dans ses fonctions…
Pagination
- ‹ Previous page
- 1
- …
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- …
- 120
- › Next page